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Abstract 
For many years, the presence of yessotoxins (YTXs) in shellfish has contributed to the 
outcome of the traditional mouse bioassay and has on many occasions caused closure of 
shellfisheries. Since YTXs do not appear to cause diarrhoea in man and exert low oral toxicity 
in animal experiments, it has been suggested that they should be removed from regulation. 
Before doing so, it is important to determine whether the oral toxicity of YTXs is enhanced 
when present together with shellfish toxins known to cause damage to the gastrointestinal 
tract. Consequently, mice were given high doses of YTX, at 1 or 5 mg/kg body weight, either 
alone or together with azaspiracid-1 (AZA1) at 200 µg/kg. The latter has been shown to 
induce damage to the small intestine at this level. The combined exposure caused no clinical 
effects, and no pathological changes were observed in internal organs. These results 
correspond well with the very low levels of YTX detected in internal organs by means of LC-
MS/MS and ELISA after dosing. Indeed, the very low absorption of YTX when given alone 
remained largely unchanged when YTX was administered in combination with AZA1. Thus, 
the oral toxicity of YTX is not enhanced in the presence of sub-lethal levels of AZA1. 
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Introduction  
The presence of yessotoxin (YTX), a disulphated polycyclic ether toxin, was first reported in 
scallops (Patinopecten yessoensis) in 1987 (Murata et al., 1987). The toxin was then found 
together with okadaic acid group toxins (OA/DTXs) that are well known for causing 
diarrhetic shellfish poisoning (DSP) in man (Yasumoto et al., 1978). YTX and its analogues 
(YTXs) are produced by the dinoflagellate algae Protoceratium reticulatum (Satake et al., 
1997; Satake et al., 1999; Ciminiello et al., 2003; Samdal et al., 2004), Lingulodinium 
polyedrum (Draisci et al., 1999) and Gonyaulax spinifera (Rhodes et al., 2006). In recent 
years, YTXs have been reported in shellfish from many countries, including Japan, New 
Zealand, Australia, Canada, Italy, France, Norway and the United Kingdom 
(FAO/IOC/WHO, 2004; Amzil et al., 2008). YTXs may contribute significantly to the 
outcome of the traditional mouse bioassay for DSP toxins when injected intraperitoneally 
(i.p.). However, the mechanisms of action of OA/DTXs and YTXs are different, since it has 
been found that YTXs, in contrast to OA/DTXs, do not inhibit protein phosphatases (Ogino et 
al., 1997). The only pathological changes observed upon i.p. injection of YTXs is in the heart 
muscle (Aune  et al., 2002; Tubaro et al., 2003) and no diarrhetic effect is observed after 
either i.p. or oral administration (Aune et al., 2002; Tubaro et al., 2003; Tubaro et al., 2004). 
The lack of documented cases of human poisoning with YTX is consistent with the very low 
acute oral toxicity of YTX generally demonstrated in experimental animals (Ogino et al., 
1997; Aune et al., 2002; Tubaro et al., 2003; Paz et al., 2008; Munday et al., 2008; Tubaro et 
al., 2008), although varying results have been obtained with respect to the effect on the heart 
muscle, studied by electron microscopy, after repeated oral exposure to YTX. In one study, 
mice given 5 mg/kg YTX by gavage seven times in three weeks did not show adverse effects 
(Espenes et al., 2006) whereas, in a separate study, mice given 1 mg/kg YTX daily for one 
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week showed changes in cardiac muscle 24 h and 30 d after the last treatment (Tubaro et al., 
2008). 
The very low oral toxicity of YTX has prompted discussion as to whether the YTXs should be 
deregulated in the EU, and in a recent recommendation from the European Food Safety 
Authority (EFSA, 2008), an acute reference dose for YTX of 25 µg/kg was suggested, based 
on the no-observed-adverse effect level (NOAEL) of 5 mg/kg. Depending on the consumption 
of contaminated shellfish, the derived maximum acceptable level of YTX in shellfish will 
vary between 3.75 mg/kg (400 g portion) and 15 mg/kg (100 g portion). This recommendation 
is in strong contrast to today’s EU regulatory level of 1 mg/kg YTX-equivalents in shellfish 
meat. 
Before YTXs are considered for deregulation, it is important to know whether their low oral 
toxicity might be enhanced by simultaneous presence of shellfish toxins acting on the 
gastrointestinal tract, for example azaspiracids (AZAs) and OA/DTXs. Both the AZAs and 
the OA/DTXs cause damage to the small intestine (Terao et al., 1986; Ito and Terao, 1994; Ito 
et al., 2000; Ito et al., 2002a; Ito et al., 2002b). The main effect of AZAs in humans is severe 
diarrhoea, together with nausea, vomiting and abdominal cramps, similar to the symptoms of 
DSP (McMahon and Silke, 1996). However, unlike OA/DTXs, AZAs do not inhibit protein 
phosphatases (Twiner et al., 2005). The AZAs affect the cytoskeleton (Roman et al., 2002), 
and studies have shown that AZAs are able to disrupt the paracellular barrier in cells in the 
GI-tract, thus increasing fluid secretion (Ryan et al., 2006). 
Both YTXs and AZAs has been observed in shellfish from the same locations in several 
countries (Twiner et al., 2008; Amzil et al., 2008; Ueoka et al., 2009; Hess, 2010) including 
Norway (Norwegian National Surveillance Program 2000-2010, unpublished data). Thus, an 
experiment was set up to study whether combined oral exposure (by gavage) of mice with 
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AZA1 and YTX would lead to increased uptake of either toxin, or to more severe toxic effects 
in the heart or other internal organs compared to the effects caused by each toxin alone. 
 
Materials and Methods 
Toxins: AZA1 used in this study was an aliquot of the certified AZA1-stock produced in 
2006, namely lot 2006/07/19 of NRC CRM-AZA1 (NRC-CNRC, 2007). The aliquot had been 
set aside after NMR-characterization of the whole lot and was stored in methanol at −80 °C, a 
condition under which no degradation of AZA1 was observed during a 12-month stability 
study (Perez et al., 2010). The isolation procedure has been briefly described by Ronzitti et al. 
(2007). Gravimetry, LC-MS and NMR have been used in the certification of the purified 
AZA1, and the certification process and uncertainties are described elsewhere (Perez et al., 
2010). The purified toxin, provided in ampoulled aliquots of 40.7 µg/mL in methanol, was 
used as a stock solution. Some impurities were identified at concentrations ranging from 0.4 
to 2.8%, relative to AZA1. The major impurity (2.8%) was an isomer of AZA1, while AZA3 
and dehydro-AZA3 were present at 0.4 and 0.7%, respectively. YTX was purified and stored 
in methanol solution to prevent decomposition as described by Loader et al. (2007). The 
purity of this material was estimated to be >95% from NMR analysis (see supporting 
information from Loader et al. (2007)) and its concentration was determined by LC-MS/MS 
analysis relative to a certified standard of YTX from NRC (NRC-CNRC, 2006). 
Other chemicals: Ethanol (96%, from Arcus, Norway), methanol and acetonitrile 
(HiperSolve, BDH Prolabo, VWR), formic acid (pro analysis, Merck, Germany) and 
ammonium formate (pro analysis, Carl Roth, Karlsruhe, Germany) were obtained from VWR, 
Norway. Saline solution (0.9 %) was prepared at the Norwegian School of Veterinary 
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Science. Deionised water (grade I) from a Milli-Q system (Millipore, MA, USA) was used in 
all preparations requiring aqueous solutions. 
Animals: Female NMRI mice, weighing between 19 and 22.5 g were used. The NMRI mouse 
is a Swiss mouse strain, originating from Lynch, and obtained by the Naval Medical Research 
Institute, USA (NMRI). It was established at M&B A/S (now Taconic Europe, Bomholt, 
Denmark), in 1961 and again in 1985, where it is maintained as an outbred stock. The mice 
had access to feed and water ad libitum. Day-length (12/12), temperature (20-22 degrees C) 
and humidity was monitored. An ethical permit was obtained for the animal trials from the 
Norwegian Animal Research Committee. 
Solutions for study of combined toxicity of AZA1 and YTX: Two 500 µg aliquots of YTX in 
MeOH were combined and the solvent was evaporated under nitrogen to give a white solid. 
This was re-dissolved immediately in MeOH to give 2000 µg/mL as a stock solution. The 
calculated volumes (Table 1) of the YTX stock solutions were dispensed into vials, which 
were capped and stored at −20 °C until required for preparation of doses. Immediately prior to 
dosing, the YTX solutions were evaporated to dryness (gentle stream of nitrogen at ca 35 °C). 
Then AZA1 stock (395 µL) was added as appropriate. The contents of all vials were 
evaporated to dryness under nitrogen and dissolved in 40 µL of 96% EtOH (vortex mixer) 
whereupon 960 µL saline was added with vortex-mixing. The clear colourless solutions were 
then taken directly to the animal facility and used in the dosing experiment. Volumetric 
transfers of toxin solutions and solvents were performed with 500 µL or 100 µL Hamilton 
syringes. Saline was dispensed with a 1 mL air-displacement pipette (Finnpipette). 
 
Animal experiments: 
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Yessotoxin was given by gavage at 1 or 5 mg/kg, either alone or in combination with AZA1 
at 200 µg/kg. A fifth group of mice received 200 µg/kg AZA1 alone while a group of control 
mice were given vehicle only. Each mouse was dosed a volume of 250 µL per 20 g b.w. The 
groups consisted of three mice except the control group which consisted of six mice. All mice 
were sacrificed after 24 h. 
The mice were killed by cervical dislocation. Tissue samples were immediately taken from 
brain, heart muscle, lungs, thymus, liver, spleen, kidneys, stomach, small intestine 
(duodenum, middle and lower jejunum) and colon for fixation in formalin. One half of the 
brain was fixed in toto and cut in three transverse sections through the level of frontal cortex, 
midbrain and cerebellum. All the fixed tissues were dehydrated, embedded in paraffin wax, 
and sections were stained with haematoxylin and eosin. For analysis of AZA1 and YTX, 
blood (from large blood vessels in thoracic cavity) and samples from the tissues mentioned 
above were collected and frozen. For electron microscopy, two pieces of tissue from the heart 
muscle less than 1 mm in diameter were fixed in 3% glutaraldehyde in 0.1 M cacodylate 
buffer, treated with OsO4 and embedded in Epon. Ultrathin sections from each embedded 
tissue block were stained with uranyl acetate and lead citrate and examined in a Philips 
EM208S electron microscope. 
All the tissue samples from stomach and intestines for ELISA and LC-MS/MS analysis had 
the digestive contents removed mechanically before they were homogenised and extracted. 
 
Chemical analyses: 
Extraction: Samples of tissues were pooled all 3 animals  in each group of mice  receiving AZA1 
and YTX, and 4 of 6 controls. Pooled samples of the organs in each group were transferred to 
capped pre-weighed 15-mL polypropylene centrifuge tubes (NUNC A/S, Roskilde, 
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Denmark), weighed, and stored at –80°C until analysis. The tissues (0.5 g portion of pooled 
liver homogenate and 0.1–0.6 g of pooled tissue from the other organs) were homogenized in 
2.0 mL MeOH with water bath cooling using an Ultra-turrax® (Ika, Germany) at 15,000 rpm 
for 30–60 s. The homogenised samples were centrifuged at ~1500 g for 20 min, left in the 
refrigerator overnight and then centrifuged again at ~1500 g for 20 min the following day. 
Aliquots of supernatants were transferred to HPLC vials for analysis, and the remainder 
stored in capped vials at –80°C for later study (ELISA). 
LC-MS/MS: Analysis was performed on an LC-MS/MS system consisting of an Agilent 1200 
HPLC system connected to an Agilent G6410 MS/MS (Santa Clara, CA, USA). The column 
used was a Hypersil BDS C8 (3.5 µm, 2.0 × 50 mm) (Thermo Fisher Scientific, Waltham, 
MA, USA). A gradient elution was run with two mobile phases; water (A) and 95% 
acetonitrile (B), each containing 50 mM formic acid and 2 mM ammonium formate (Table 2), 
based on Quilliam et al. (2001). The AZA1 and YTX used for dosing were analysed by 
selected reaction monitoring (SRM) for the transitions characteristic for AZA1, AZA2 and 
AZA3 (m/z 842.5, 856.5 and 828.5 → 362.5) and YTX, 45-hydroxyYTX and carboxyYTX 
(m/z 1141.5, 1157.5 and 1173.5 → 855.5). The samples were quantified against standards for 
AZA1 and YTX from the CRM program of IMB, NRC, Halifax, NS, Canada. 
ELISA: Sample preparation: Extracts for ELISA analysis were prepared by serial three-fold 
dilutions with phosphate-buffered saline with 0.05% Tween 20 (PBST) and sample buffer 
(10% methanol in PBST) to give a final methanol concentration of 10%. ELISA quantitation 
was performed at three dilutions out of 1:10, 1:30, 1:90, 1:270, 1:810 and 1:2430 (usually 
1:10, 1:30, 1:90 or 1:270), as appropriate. 
Reagents: ELISA analysis (Briggs et al., 2004) was performed with a quantitative YTX 
standard obtained by dilution of the dosing solution and calibrated by LCMS against the 
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certified NRC standard. Ovine antibodies to YTXs (serum #505) were obtained from 
AgResearch Ltd, Hamilton, New Zealand (Briggs and Miles, 1999; Briggs et al., 2004). 
Horseradish peroxidase (HRP)-coupled rabbit anti-sheep antibodies were purchased from 
Zymed Laboratories (61-8620; now distributed by Invitrogen, Camarillo, CA, USA). 
Substrate was K-Blue® Aqueous Substrate (TMB) from Neogen (Lexington, USA). OVA-
BrYTX-coater was prepared as described by Briggs et al. (2004) and all other reagents for the 
YTX-ELISA were prepared according to Samdal et al. (2004). 
ELISA analysis: The concentration of YTXs in each mouse tissue sample extract was 
determined by indirect competitive ELISA as described by Briggs et al. (2004), with only 
minor adjustments to plate coater and antibody concentrations to optimize the assay (Samdal 
et al., 2004). All incubations were performed at room temperature. YTX standard in methanol 
(1 μg/mL) was diluted in PBST and sample-buffer (10% methanol in PBST), to give a 
methanol concentration of 10%. Serial three-fold dilutions of the YTX standard were 
performed with sample buffer, giving 10 standards from 0.002–40 ng/ml. Serial dilutions of 
standards and samples were performed in duplicate. Absorbances were measured at 450 nm 
using a plate reader (Wallac 1420 Victor2 multilabel counter, Wallac, Turku, Finland). 
 
Results 
Very low levels of YTX were found in internal organs when mice were given YTX by gavage 
at 1 or 5 mg/kg (Fig. 1, Table 3). The level of quantification for YTX was exceeded only in 
kidneys, spleen, liver and lungs. Considerably higher levels of YTX were recovered from 
tissue samples from the GI tract. When mice were exposed to combinations of either 1 or 5 
mg/kg YTX together with AZA1 at 200 μg/kg, the level of YTX in internal organs remained 
very low (Fig. 2, Table 3). In Fig. 2, only data from AZA1 together with the highest YTX 
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dose are given, due to the very low levels of YTX at 1 mg/kg. A very large increase in YTX-
levels was observed in stomach tissue when YTX, at both levels, was combined with AZA1, 
whereas the levels found in the small and large intestines were similar to the levels when 
YTX was given alone. 
An estimate of the total amount of YTX detected by LCMS in different internal organs 24 h 
after gavage is shown in Table 4. When given alone, the amount of YTX recovered from each 
internal organ was below 0.05% of the total amount given, regardless of the YTX dose given. 
The amount of YTX  in the heart and brain were below the limit of quantification. When co-
administered with AZA1 (200 μg/kg), the levels of YTX in organs remained essentially 
unchanged (Table 4).  
The effect of the combination of YTX with AZA1 was also studied concerning effects on 
absorption of AZA1 from the GI-tract (Fig. 3). The absorption of AZA1 was considerably 
higher than that of YTX. Co-administration with YTX did not enhance the absorption of 
AZA1.  
Analyses of YTX were performed both with LC-MS and ELISA, since only YTX and main 
analogues are quantified by the LC-MS, while a whole range of analogues/metabolites are 
detected by ELISA (Aasen et al. 2005, Briggs et al., 2004; Samdal et al., 2005). Results of both 
methods corresponded well to each other in samples from the GI tract, whereas the YTX 
levels in internal organs were consistently higher by ELISA than by LC-MS (Table 3 and 
Supporting Information). However, YTX levels in internal organs were very low, increasing 
the uncertainty in both methods. Nevertheless, the correlation between the two methods for 
the different tissues was examined using linear regression. The correlation ratios were 1.1 (R2 
0.999) for the stomach, 1.4 (R2 0.99) for the duodenum, 1.2 (R2 0.94) for the jejunum, 1.5 (R2 
0.97) for the ileum, and 1.9 (R2 0.94), suggesting a low level of metabolism during passage 
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through the GI tract. The correlation ratios for internal organs were 1.3 (R2 0.89) for lung, 2.2 
(R2 0.85) for spleen, 1.6 (R2 0.74), and 3.8 (R2 0.90) for kidney. These results suggest a 
degree of metabolism of YTX within the internal organs of the mouse. 
The mice were observed for 24 h, and no clinical signs of disease were observed for the 
period, either for those exposed to AZA1 or YTX alone or for those exposed to the 
combination of the two compounds. 
Macroscopical pathology: Mice that had received AZA1 alone showed considerable retention 
of material in the stomach and the upper ⅓ of the small intestine was dilated with increased 
fluidity of the content compared with control animals. Mice that received a combination of 
YTX and AZA1 showed similar changes to those that had received AZA1 only, at both 1 and 
5 mg/kg YTX. In mice that had received only YTX at 1 and 5 mg/kg, no changes were 
observed compared to the control mice. 
Microscopical pathology: In mice that had received YTX at 1 or 5 mg/kg in combination with 
AZA1 at 200 μg/kg, the villi in the duodenum appeared contracted, blunt and occasionally 
club-shaped, the cryptal compartments were extended and an extensive infiltration of 
polymorphonuclear granulocytes (neutrophils) were noted in the lamina propria. These 
changes were similar to the changes observed in the duodenum of mice that had received 
AZA1 alone (Fig. 4). In mice that had been given YTX alone, the duodenum was normal and 
similar to the duodenum in control mice. By light microscopy, no changes were observed in 
any of the other organs examined including the other intestinal segments. 
By electron microscopy, no changes were found in the heart muscle, either in the group given 
a combination of AZA1 and YTX or in the group given YTX alone. The myocardial cells 
surrounding the capillaries showed no signs of cytoplasmic swelling or abnormal 
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mitochondria (Fig. 5) and the general structure of the myofibrils and distribution and structure 
of the mitochondria were found normal (Fig. 6). 
 
Discussion 
The present study examined the effect of oral exposure of mice to the marine algal toxins 
AZA1 and YTX and combinations thereof. Such co-exposure could potentially have led to 
new or enhanced toxic effects that are not observed when the toxins are administered 
separately. In particular, we wondered if the pathological changes caused by AZA1 in the 
intestine (Ito et al., 2000; Ito et al., 2002b; Aasen et al., 2010) could damage the mucosal 
barrier and increase the absorption of YTX, and thereby cause systemic effects similar to 
those observed after intraperitoneal (i.p.) injection of YTX (Terao et al., 1990; Aune et al., 
2002; Tubaro et al., 2003). Very low concentrations of YTX were measured in kidneys, 
spleen, liver and lungs, when YTX at 1 or 5 mg/kg was given alone (Fig. 1, Table 3). In 
blood, the YTX level was below the LOQ by LC-MS in all groups except in the group given 
YTX at 5 mg/kg together with AZA1, where the YTX level was very low. When using 
ELISA, the YTX concentration in blood was slightly higher, and corresponded well with the 
results reported by Tubaro et al. (2008). 
The level of YTX in the heart, the putative target organ when YTX is given i.p., was below 
the level of quantification by LC-MS. This corresponds well with previous data showing no 
significant difference between mice exposed to YTX and controls after repeated oral 
exposures, i.e. a dose of up to 5 mg/kg YTX given seven times during three weeks (Espenes 
et al., 2006). However, other studies have indicated that YTX can induce ultrastructural 
changes in the heart muscle of mice both after short term exposure (Aune et al., 2002) and 
after repeated daily exposures of 1 or 2 mg/kg for one week (Tubaro et al., 2004; Callegari et 
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al., 2006; Tubaro et al., 2008). In the present study, the YTX levels in internal organs were 
very low, suggesting that only a small proportion of YTX is transported across the intestinal 
barrier. However, only one time point and a limited number of organs were analysed, so 
detailed information on the absorption and distribution of YTX could not be obtained. The 
total fraction of YTX in the internal organs measured by LC/MS accounted for less than 0.1% 
of the administered dose   (Table 4). Most of the toxin presumably passed through the animals 
since most of the YTX was recovered from the lower intestine and the faeces, while only trace 
amounts were found in blood, urine and tissues. (Munday et al., unpublished results). 
The level of YTX in the stomach was around two orders of magnitude higher when YTX was 
given in combination with AZA1, compared to when YTX was given alone (Table 3). Since 
the stomach content was only mechanically removed before the toxin level was measured, a 
sharp distinction between toxin level in the content and the stomach wall could not be made.  
The observed increase in retention of the stomach contents, suggest an inhibitory effect of 
AZA1 on the motility of the stomach and duodenum, which would extend the period with 
high YTX levels in the stomach. Another possible explanation is that the combination induced 
absorption of YTX into the stomach wall, but this is less likely since such an absorption ought 
to have resulted in higher toxin levels in the liver and/or other internal organs. However, since 
the YTX concentration in the distal parts of the intestines was similar to when YTX was given 
alone (Table 3 and Fig. 2), it seems that the motility of the stomach and intestines is not 
severely inhibited due to AZA1 but rather slowed. It may be assumed that the part of the 
intestine with pathological changes has been exposed to a substantial amount of YTX. 
The concentrations of AZA1 found in the different tissues when given in combination with 
YTX were similar to the levels when AZA1 was given alone at 200 µg/kg (Fig. 3). These 
results were also similar to those obtained in Aasen et al. (2010) for AZA1 at 200 µg/kg. 
Consequently, YTX does not seem to influence the absorption of AZA1. 
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In mice exposed to a combination of AZA1 and YTX, the pathological changes in the 
intestine were similar to the changes caused by AZA1 alone. The damage to the intestine did 
not appear to increase the absorption of YTX as shown by the quantification of YTX in blood 
and internal organs by LC-MS. The levels found in the blood by LC-MS and ELISA (Table 3) 
corresponded with the levels reported by Tubaro et al., (2008). The low YTX levels in the 
internal organs were consistent with the histological investigations by light microscopy 
showing normal morphology in the same organs. 
It is possible that the YTX concentration in internal organs could have been higher at a time 
point earlier than 24 h, or that YTX could have been modified in the tissues to analogues not 
detectable by the LC-MS method. However, lack of pathological changes strongly indicates 
that a high YTX concentration in the tissues had not been present during the first 24 h as this 
has been shown to be within the time limit to induce changes in tissues (Aune et al., 2002; 
Tubaro et al., 2003). The ELISA measurement of YTXs did not show the presence of a high 
proportion of analogues in most tissues, supporting the LC-MS data obtained in the present 
study but indicating the potential for a degree of metabolism in internal organs of mice. 
To more precisely address possible changes in the presumed target organ for YTX, the heart 
muscle, ultrastructural studies were performed. As early as 1990, Terao et al. reported the 
toxic effects of YTX upon i.p. exposure of mice. The animals died within a few hours at doses 
of 300 µg/kg. Subsequent studies have confirmed the high lethality of YTX when given via 
the i.p. route (Terao et al., 1990; Ogino et al., 1997; Aune et al., 2002; Tubaro et al., 2003; 
Aune et al., 2008). YTX given i.p. caused changes in the cardiac muscle with oedema and 
vacuolation (Aune et al., 2002). The degree of damage to the heart has varied in different 
studies. Terao et al. (1990) reported swelling and degeneration of the endothelial lining cells 
of the left ventricle and swelling of most cardiac muscle cells at 500 µg/kg of YTX when 
given i.p., and Aune et al. (2002) reported less severe changes in the heart after i.p. doses of 
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1,000 µg/kg one hr after injection, with swelling and separation of myofibrils and 
mitochondria of myocardial cells in the left ventricle, most pronounced near the capillaries. 
The effects of oral exposure have been more variable, as Terao et al. (1990) found no effects 
on the heart 21 h after exposure to YTX at 0.5 mg/kg whereas Aune et al. (2002) described 
such changes in mice 24 h after oral dosing with 7.5 and 10 mg/kg and 1 h after dosing of 2.5, 
5 and 10 mg/kg, although in the latter group the changes were moderate for the lowest dose. 
Even doses of 1 and 2 mg/kg YTX given orally have been reported to induce ultrastructural 
changes in heart muscle cells 24 h after adminstration although no signs of toxicity and no 
indication of cardiac tissue damage based on plasma enzyme measurements, were noted 
(Tubaro et al., 2003). In the present study, no ultrastructural changes were seen in the heart 
muscle 24 h after 1 or 5 mg/kg of YTX, either alone or in combination with AZA1, findings 
that were consistent with the very low level of YTX that was detected in the heart muscle 
(Figs. 5 and 6, Tables 3 and 4). In this study, the concentration of toxins found in the internal 
organs of the mice was measured by LC-MS based on the method of Quilliam et al. (2001). 
This method has some limitations in that it has not been optimised for mouse tissues (Aasen et 
al., 2010). However, the method has been used for the analysis of several matrices in our lab, 
and was the best alternative available for quantification of low concentrations of AZA1 and 
YTX. 
The LC-MS analysis could potentially be influenced by matrix effects from the different 
organs, but we were not able to study this phenomenon in the present work. However, since 
one of the major aims in this study was to compare the effects of different treatments on the 
concentration of YTX in the same organ, the possible matrix effects are likely to be minor. 
The ELISA method for YTX is expected to give higher figures than the LC-MS method if 
other analogues or metabolites of YTXs are present. With the LC-MS method, only YTX and 
two main analogues were measured, while with ELISA, all those YTX analogues that have an 
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intact part of the ladder were measured (Briggs et al., 2004; Samdal et al., 2005). The results 
obtained with ELISA indicate that metabolism of YTX was generally modest, as the results 
were close to those obtained by LC-MS where YTX was the only analogue detected. 
The limit of quantification (LOQ) for AZA1 with the LC-MS method was approximately 0.35 
ng/mL and for YTX 0.5 ng/mL, while the limit of detection (LOD) was below 0.1 ng/mL for 
both toxins. The tissue samples were pooled from all animals treated, but the total weight was 
still relatively low for some of the organs. This low sample mass increases the uncertainty of 
the analysis, since the concentration in the extracts (ng/mL) was multiplied by extraction 
volume and divided by weights of the sampled organs to estimate the concentrations of toxins 
(µg/kg).  
In conclusion, we report that oral exposure of mice to 1 or 5 mg/kg YTX, either alone or 
together with AZA1 at 200 µg/kg (a level that causes damage to the small intestine (Aasen et 
al., 2010)), does not lead to enhanced absorption of YTX nor to toxic effects in the heart or 
other internal organs. These results support the suggestion to deregulate YTXs in shellfish, 
especially since the most resent risk assessment by the EU Panel on Contaminants in the Food 
Chain (2008)  recommend a considerably higher acute reference dose for the YTX-group. 
Supporting Information 
Plot of ELISA (YTXs) versus LC/MS (YTX) results for tissues from mice dosed with YTX (1 
and 5 mg/kg) alone and in combination with AZA1 (200 µg/kg), with linear least squares 
correlations fitted in Excel. 
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Captions for Figures and Tables 
Figure 1. Concentrations of YTX (by LC/MS) in µg/kg in tissues of female NMRI mice, after dosing 1 
mg/kg and 5 mg/kg YTX by gavage. 
 
Figure 2. Concentrations of YTX (by LC/MS) in µg/kg in tissues of female NMRI mice, when given 
alone at 5 mg/kg and in combination with 200 µg/kg AZA1. 
 
Figure 3. Concentrations of AZA1 in µg/kg in tissues of female NMRI mice after dosing of 200 µg/kg 
AZA1 alone and in combination with 1 mg/kg and 5 mg/kg YTX. 
 
Figure 4. Representative micrographs of duodenum from mice killed 24 h after oral exposure to either 
(A) vehicle, (B) AZA1 alone, 200 µg/kg, (C) YTX 5 mg/kg alone or (D) a combination of AZA1, 200 
µg/kg and YTX, 5 mg/kg. Mice exposed to AZA1 alone or the combination of AZA1 and YTX 
showed shortened villi, elongated crypts and accumulation of inflammatory cells in lamina propria 
(arrows). Mice exposed to YTX alone did not show changes. HE-stain. Bar: 100 µm. 
 
Figure 5. Representative electron micrographs of heart muscle of mice. Normal structure of capillaries 
(cap) and adjacent myocardial cells of a control is shown in A. There were no changes in myocardial 
cells close to the capillaries, either in mice orally exposed to YTX alone (B) or to a combination of 
AZA1, 200 µg/kg and YTX, 5 mg/kg (C). In all groups, the myocardial cells contained many 
mitochondria (arrows). Bar: 1 µm. 
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Figure 6. Electron micrographs of heart muscle. There were no changes in myocardial cells related to 
the structure of the myofibrils or the morphology or distribution of mitochondria (arrows) either in 
mice orally exposed to a combination of azaspiracid-1 at 200 µg/kg and yessotoxin at 5 mg/kg (B) nor 
as compared to mice exposed to vehicle only (A). Bar: 2 µm. 
 
Table 1. Calculated volumes of AZA1 and YTX stock solutions for dilutions 
 
Table 2. HPLC gradient program with two-phase gradient of water (A) and 95% acetonitrile (B), each 
containing 50 mM formic acid and 2 mM ammonium formate 
 
Table 3. Levels of YTX (µg/kg) found by LC-MS/MS and by ELISA in mouse tissues. LOQ values 
for each sample given 
 
Table 4: Average weight of internal organs of 20 g female NMRI mice and estimates of total amount 
of YTX (ng) determined by LCMS in internal organs of mice 24 h after oral intubation at two doses, 
with and without AZA1 (200 µg/kg), and estimated percentage of dosed YTX recovered in each 
organ. LOQ in ng for each organ in separate column.  
 
 
 
